Señales en vivo de 688185.SS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 03:00):

Stats
Volumen de hoy	1.93M
Volumen promedio	1.57M
Capitalización de mercado	7.18B
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-8.98
ATR14	CNY0.0690 (0.13%)

Volumen Correlación

Largo: -0.24 (neutral)

Corto: -0.01 (neutral)

Signal:(43.515) Neutral

CanSino Biologics Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CanSino Biologics Inc. Correlación - Moneda/Commodity

0.55
( weak )

0.53
( weak )

0.00
( neutral )

0.57
( weak )

0.67
( moderate )

-0.61
( weak negative )

CanSino Biologics Inc. Finanzas

Annual	2023
Ingresos:	CNY349.12M
Beneficio Bruto:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2023
Ingresos:	CNY349.12M
Beneficio Bruto:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2022
Ingresos:	CNY1.03B
Beneficio Bruto:	CNY-186.61M (-18.10 %)
EPS:	CNY-3.91

FY	2021
Ingresos:	CNY4.30B
Beneficio Bruto:	CNY3.00B (69.85 %)
EPS:	CNY7.74

Financial Reports:

No articles found.

CanSino Biologics Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.